Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that the Company will participate in a panel discussion and fireside chat at the H.C. Wainwright 26th Annual Global Healthcare Conference taking place September 9-11, 2024 in New York.
Details are as follows:
Panel: Cutting-Edge Approaches to Viral Hepatitis: Is a Cure on the Horizon?
Date: September 9, 2024
Time: 11:00-12:00PM ET
Presenter: Cassie Gorsuch, Ph.D., Vice President, Gene Therapy Discovery
Fireside Chat:
Date: September 10, 2024
Time: 5:00-5:30PM ET
Webcast Registration: Link
The Fireside Chat will be available on Precision’s website in the Investors section under Events & Presentations on at investor.precisionbiosciences.com. An archived replay will be available for approximately 30 days following the event. Please contact your H.C. Wainwright representative for details regarding access to the panel presentation.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904336857/en/
Contacts
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
